European AIDS Treatment Group·2 min read·medium
Results of the CAPRISA 012c clinical trial of a combination of two bnAbs to prevent HIV infection in young women in southern Africa announced at AIDS 2026
H
https://www.facebook.com/EuropeanAIDSTreatmentGroup
✦AI Summary
Researchers at the AIDS 2026 conference announced results from a Phase II clinical trial of long-acting broadly neutralizing antibodies (bnAbs) for HIV prevention. The study specifically targets young women aged 15-24 in sub-Saharan Africa.
Young women 15-24 years in sub-Saharan African continue to bear the brunt of the HIV epidemic. Researchers from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) announced the results of a Phase II clinical trial evaluating long-acting broadly neutralising antibodies (bnAbs) for preventing HIV infection in young women at AIDS 2026.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in